Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval From USFDA for type 2 Diabetes Tablets
Details : Empagliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally).
Product Name : Empagliflozin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivermectin
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Gets USFDA Nod for Ivermectin Cream
Details : Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Product Name : Ivermectin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : Ivermectin
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interferon Alpha-2B
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cadila Healthcare's Hepatitis C Drug Gets Approval for Emergency Use
Details : About 91 per cent of patients treated with the Pegylated Interferon Alpha-2b, tested negative for Covid-19 in standard RT-PCR tests by day seven, compared to nearly 79 per cent who were given the standard of care, the company said earlier this month.
Product Name : PegiHep
Product Type : Protein
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Interferon Alpha-2B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable